Navigation Links
YM BioSciences announces FDA clearance for two ongoing Phase II nimotuzumab trials into USA
Date:1/26/2010

ur data, which support the unique selectivity of nimotuzumab for the overexpressed receptors on tumor that uniquely permit it to discriminate between normal tissue and tumor EGFR, has heightened investigator interest in advancing nimotuzumab."

Palliative radiotherapy to intrathoracic disease from non-small cell lung cancer trial

This Phase II study that is examining the effect of nimotuzumab when added to palliative radiotherapy to treat intrathoracic disease from NSCLC, has a target enrollment of 128 patients and is being conducted internationally. Patients diagnosed with Stage IIb or III NSCLC ineligible for curative treatment, or Stage IV NSCLC patients with progressive disease within the chest, are eligible to enroll into this study. Palliative radiotherapy is effective for improvement of symptoms resulting from lung disease, improvement in quality of life in one third of the patients, and improvement of survival. Completed Phase I studies executed in Canada and Korea have demonstrated that nimotuzumab has the prospect of optimizing palliative care in this indication with initial stimulating results in this population. The primary objective of the trial is to evaluate the difference in Overall Survival between the arms with secondary endpoints being the differences in Time to Progression, Response Rate, Quality of Life, and Progression-Free Survival.

Brain metastases trial

This Phase II study, comparing nimotuzumab plus whole-brain radiation therapy (WBRT) to WBRT alone in patients with brain metastases from NSCLC, has a target enrollment of 88 patients and is also being conducted internationally. The primary efficacy endpoint is the difference in intracranial disease progression over six months.

Both trials are currently open in Canada and are being extended into Europe, Korea,

SOURCE YM BioSciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
8. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... 2015 Bi-Biomics today announced a ... stain additive. The improvement in histological quality provided ... present in all daughter cells. , After processing ... was analyzed at 1000-1600x using light microscopy. ... in all daughter cells displayed predominant binary features ...
(Date:3/5/2015)... March 5, 2015  In response to the incorrect ... Miami, FL on February 12, 2015. Impeto ... strong financial health and their SUDOSCAN® devices have been ... indicated. Furthermore, Impeto prefers to have the courts decide this ... more than 40 articles written by Key Opinion Leaders, ...
(Date:3/4/2015)... March 4, 2015 In an article published ... Center for Health Security review the clinical aspects of ... used as bioweapons. The article, "Clinical Management of Potential ... the website of the New England Journal of ... Eric Toner , and Tom Inglesby—review the clinical management ...
(Date:3/4/2015)... DUBLIN , Mar. 04, 2015 Research ... announced the addition of the "Global Biologics ... their offering. , The Global ... professional and in-depth study on the current state ... The report provides a basic overview of the ...
Breaking Biology Technology:Impeto Medical Responds to Published Allegations by LD Technology LLC ("LD") 2Latest Clinical Information On Bioterrorism Threats 2Global Biologics and Biosimilars Industry Report 2015-2020 2
... and managing to duck the hype of peer-to-peer networking, ... platform based on a "grid network" to accelerate the delivery ... a clever product director, Homer has guided Kontiki around the ... to build a platform and company that serves content providers ...
... Merge eFilm , the Milwaukee-based medical imaging technology company ... momentum leading into its proposed merger with Toronto-based Cedara ... more than $10.5 million in first-quarter 2005. , ,That's ... a 19 percent year-over-year jump in net sales in ...
... team of engineers and biologists has come up with a ... very small crystals and measuring their changing response to electricity. ... on the order of a handful of molecules. , ... and Robert Blick, found they could open new electrical channels ...
Cached Biology Technology:Creating a public service for multimedia content 2Creating a public service for multimedia content 3Creating a public service for multimedia content 4Merge eFilm earnings jump precedes planned merger 2Merge eFilm earnings jump precedes planned merger 3
(Date:3/4/2015)... 04, 2015 Research and Markets ... the "Global Biometrics Market Forecast and Opportunities, ... The market for biometric authentication systems is projected ... till 2020 The driving forces for ... needs, government projects and constant development in technology. ...
(Date:3/2/2015)... , March 2, 2015   Neurotechnology , a ... introduced the SentiGaze Software Development Kit (SDK). ... applications that use off-the-shelf webcams to track eye movements ... at a monitor. Heatmaps can be used for applications ... of online advertising. The SDK can also be used ...
(Date:2/24/2015)... 2015 Research and Markets ( ... "Global 2D Gesture Recognition Market 2015-2019" ... analysts forecast the Global 2D Gesture Recognition market ... the period 2014-2019 The increased demand ... one of the major trends in the market. ...
Breaking Biology News(10 mins):Global Biometrics Market Forecast and Opportunities, 2020 2Global Biometrics Market Forecast and Opportunities, 2020 3Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 2Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 3Global 2D Gesture Recognition Market 2015-2019 with Cognitec Systems, CogniVue, eyeSight Mobile Technologies & PointGrab Dominating 2
... 2012 - The 2010 blowout of the Macondo well in ... region,s largest oil spill in U.S. history. As the Deepwater ... oil from coming to the surface and reaching coastal and ... powerful dispersants, typically used to break up oil slicks at ...
... Saito, a biogeochemist at Woods Hole Oceanographic Institution, has been ... the Gordon and Betty Moore Foundation. Saito is one of ... from a total of up to $35 million over five ... microbial ecology. "We are grateful to the Moore Foundation ...
... French . Thanks to the support of ... work together over a five-year period to translate the results ... the way for personalised medicine in CMDs. Researchers and clinicians ... be involved in the METACARDIS project. The aim of ...
Cached Biology News:Numerical study suggests subsea injection of chemicals didn't prevent oil from rising to sea surface 2Numerical study suggests subsea injection of chemicals didn't prevent oil from rising to sea surface 3WHOI scientist receives marine microbiology initiative investigator award from Moore Foundation 2METACARDIS: a European project that deciphers the genes of the gut microbiota 2METACARDIS: a European project that deciphers the genes of the gut microbiota 3
Denhardt's Solution is a mixture of blocking agents used in membrane-based hybridization protocols. The solution contains 1% Ficoll (type 400) 1% polyvinylpyrrolidone and 1% bovine serum albumin. Ste...
... CHEMICONs ELF 97 Cytological Labeling Kit ... facilitate the detection of cellular targets, including ... 97 Cytological Labeling Kit contains the patented ... brightly fluorescent yellow-green precipitate at the site ...
... H 10 O 2 S 2 ... Form: White crystalline powder Assay: greater ... By IR Melting Point: greater than ... less than or equal to 1% ...
... Fluorescence Test Plate consists of an anodized ... Inert Organic Fluorescent Compounds embedded in polymerized ... on BioTeks FLx800 and Synergy Multi-Detection Readers. ... GLP compliance while reducing the need for ...
Biology Products: